R&D Trends

Boehringer, Duke collaborate on IPF patient registry

Friday, August 26, 2016

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

[Read More]

Crown Bioscience Oncology Center in San Diego expands services

Wednesday, August 17, 2016

Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has expanded its oncology services with new models, cell lines and assays at its Center of Excellence for Oncology in San Diego.

[Read More]

UnDx Consortium to focus on precision medicine

Tuesday, August 16, 2016

UnDx Consortium has launched. This organization brings together five precision medicine technology providers and experts from medical centers and universities across the country to collaborate in an effort to produce new hypotheses for a set of six patients struggling with undiagnosed diseases. UnDx Consortium will explore results of cutting-edge tests analyzing samples from these patients and their families.

[Read More]

Catalent Biologics, Zumutor collaborate to enhanced antibodies

Thursday, August 11, 2016

Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Zumutor Biologics, a developer of biosimilars, novel biobetters and New Biological Entities, have announced a successful research study, combining Catalent’s proprietary GPEx technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies.

[Read More]